Abstract：Objective: To investigate the efficacy of vitreous cavity injection in the treatment of senile wet macular degeneration. Methods: 90 elderly patients with age-related wet macular degeneration who were enrolled from May 2014 to May 2016 were randomly divided into three groups. Group A was given vitreous cavity injection of ranibizumab and photocoagulation. Group B patients were given only ranibizumab injection the patients were given only photocoagulation in group C, and the best corrected visual acuity, central macular thickness and the trend and complication were compared between the three groups. Results: Compared with group B and group C, the difference between 1m, 3m, 6m and 12mBCVA scores was significantly higher than that of group B and group C (P <0.01). There was a significant difference between the two groups (P <0.01). There was a significant difference between the two groups (P <0.05) |There was no significant difference in the incidence of complications between the three groups (P>|0.05). Conclusion: Vitreous cavity injection of ranibizumab photocoagulation in the treatment of senile wet macular degeneration in the most significant effect, high safety, with reference.
2017, Vol. 23 
冀公网安备13080202000677号